These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


192 related items for PubMed ID: 4110630

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment.
    Bednarek J, Wysocki H, Sowinski J.
    Free Radic Res; 2004 Jun; 38(6):659-64. PubMed ID: 15346657
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T, Sato A, Komiya I, Nishimori T, Ito Y, Terao A, Eto S, Tanaka Y.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
    Bossowski A, Czarnocka B, Bardadin K, Urban M, Niedziela M, Dadan J.
    Horm Res; 2008 Aug; 70(3):155-64. PubMed ID: 18663316
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial evaluating a block-replacement regimen during radioiodine therapy.
    Bonnema SJ, Grupe P, Boel-Jørgensen H, Brix TH, Hegedüs L.
    Eur J Clin Invest; 2011 Jul; 41(7):693-702. PubMed ID: 21175612
    [Abstract] [Full Text] [Related]

  • 8. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
    Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P.
    Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
    Bossowski A, Urban M.
    J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
    Gedik O, Ozdemir T, Akalin S.
    Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE, Michanek AM, Holmberg EC, Fink M.
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [Abstract] [Full Text] [Related]

  • 15. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
    Gu X, Zheng L, Chen X, Ruan L, Zhang H, Ge S, Zhu H, Lin X, Shen F.
    Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Behavior of serum angiotensin converting enzyme in hyperthyroidism correlated to that of TSH].
    Letizia C, Sellini M, Baccarini S, Scavo D.
    Minerva Med; 1991 Jun; 82(6):333-7. PubMed ID: 1712434
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical significance of serum triiodothyronine].
    Zurcher H, Sakoloff C, Burger A, Vallotton MB.
    Schweiz Med Wochenschr; 1973 Dec 01; 103(48):1710-3. PubMed ID: 4127701
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.